Advertisement
Screener

LEXARIA BIOSCIENCE CORP. (LEXX) Overview

LEXARIA BIOSCIENCE CORP. (LEXX) Overview

  • 1 Mar 2026: Period ending 31 May 2026; Estimate (m); Actual -0.08; Beat / miss (m).
  • 1 Dec 2025: Period ending 28 Feb 2026; Estimate (m); Actual -0.06; Beat / miss (m).
  • 1 Sept 2025: Period ending 30 Nov 2025; Estimate (m); Actual -0.07; Beat / miss (m).
  • 1 Mar 2025: Period ending 31 May 2025; Estimate (m); Actual -0.21; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$2.94$4.36$6.47$9.59$14.23$21.112025-11-062026-11-06$2.94$5.99$12.21$24.88$50.70$103.322021-11-082026-11-06$2.94$6.30$13.50$28.94$62.03$132.932021-01-122026-11-06$2.94$6.30$13.50$28.94$62.03$132.932021-01-122026-11-06$2.94$6.30$13.50$28.94$62.03$132.932021-01-122026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$4.44
Previous close
$3.13
Change
$1.31
Change (%)
41.85%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

LEXX
-66.20%
S&P 500
(m)

1 year

LEXX
-78.78%
S&P 500
(m)

3 years

LEXX
-79.13%
S&P 500
(m)

5 years

LEXX
-96.68%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

31 May 2026 ○ Estimate (m) ● Actual -0.08

-0.29-0.19-0.080.020.1228 Feb 2025: estimate (m); actual -0.1528 Feb 2025(m)31 May 2025: estimate (m); actual -0.2131 May 2025(m)30 Nov 2025: estimate (m); actual -0.0730 Nov 2025(m)28 Feb 2026: estimate (m); actual -0.0628 Feb 2026(m)31 May 2026: estimate (m); actual -0.0831 May 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Mar 202631 May 2026(m)-0.08(m)(m)
1 Dec 202528 Feb 2026(m)-0.06(m)(m)
1 Sept 202530 Nov 2025(m)-0.07(m)(m)
1 Mar 202531 May 2025(m)-0.21(m)(m)
1 Dec 202428 Feb 2025(m)-0.15(m)(m)

31 Aug 2025 ○ Estimate (m) ● Actual -0.66

-1.09-0.78-0.48-0.170.1431 Oct 2010: estimate (m); actual -0.0431 Oct 2010(m)31 Oct 2011: estimate (m); actual -0.0431 Oct 2011(m)31 Aug 2023: estimate (m); actual -1.0131 Aug 2023(m)31 Aug 2024: estimate (m); actual -0.4731 Aug 2024(m)31 Aug 2025: estimate (m); actual -0.6631 Aug 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Sept 202431 Aug 2025(m)-0.66(m)(m)
1 Sept 202331 Aug 2024(m)-0.47(m)(m)
1 Sept 202231 Aug 2023(m)-1.01(m)(m)
1 Nov 201031 Oct 2011(m)-0.04(m)(m)
1 Nov 200931 Oct 2010(m)-0.04(m)(m)

Revenue vs. Earnings

USD

31 May 2026 ■ Revenue 0.00M ■ Earnings -1.99M — Profit margin (m)

-4.26M-7250.9%-2.63M-5559.5%-0.99M-3868.1%0.65M-2176.6%31 May 2025: revenue 0.17M; earnings -3.79M; profit margin -2177.64%31 May 202530 Nov 2025: revenue 0.00M; earnings -1.60M; profit margin (m)30 Nov 202528 Feb 2026: revenue 0.02M; earnings -1.45M; profit margin -7249.89%28 Feb 202631 May 2026: revenue 0.00M; earnings -1.99M; profit margin (m)31 May 2026

31 Aug 2025 ■ Revenue 0.71M ■ Earnings -11.90M — Profit margin -1686.00%

-13.41M-2947.4%-8.20M-2380.7%-2.99M-1814.0%2.22M-1247.2%31 Aug 2022: revenue 0.26M; earnings -7.27M; profit margin -2846.28%31 Aug 202231 Aug 2023: revenue 0.23M; earnings -6.66M; profit margin -2946.36%31 Aug 202331 Aug 2024: revenue 0.46M; earnings -5.80M; profit margin -1248.25%31 Aug 202431 Aug 2025: revenue 0.71M; earnings -11.90M; profit margin -1686.00%31 Aug 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$4.44(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$4.44High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning LEXX

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-12; financial period ending 31 May 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-7.73M
Profit margin
-3985.58%
Return on assets · 12 month
-134.21%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
93.11K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-2.80%*
Total return · month
-69.76%*
Total return · quarter
-63.35%*
Total return · half year
-71.88%*
Total return · year to date
-66.20%*
Total return · 1 year
-78.78%*
Total return · 3 years
-79.13%*
Total return · 5 years
-96.68%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$194.00K
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

LEXARIA BIOSCIENCE CORP. Overview

View more →

(m)

(m)

SEC CIK
1348362
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
(m)
Business address
100 - 740 MCCURDY ROAD, KELOWNA, V1X 2P7
Fiscal year end
0831
Phone
250-765-6424

Similar stocks

Stock NameCountryMarket CapPE Ratio
Telomir Pharmaceuticals, Inc. (TELO)United States$0.084B
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Rallybio Corp (RLYB)United States$0.089B
Lifevantage Corp (LFVN)United States$0.078B15.40
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
Valion Bio, Inc. (VBIO)United States$0.077B
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30